NasdaqGS:MEDPLife Sciences
Medpace Holdings (MEDP) Is Up 7.8% After GLP-1 Trials Drive 32% Revenue Jump – What’s Changed
In the fourth quarter of 2025, Medpace Holdings reported a 32% year-over-year revenue increase, while Mairs & Power Small Cap Fund cited the company as a key contributor in its investor letter due to stronger clinical trial trends linked to GLP-1 programs.
This combination of healthier trial cancellation patterns and momentum in GLP-1 research highlights how Medpace is benefiting from current demand in metabolic-related clinical development.
We’ll now explore how this improved GLP-1-driven...